NCT04897139View on ClinicalTrials.gov

Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT

PHASE2RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

June 1, 2024

Study Completion Date

December 1, 2024

Conditions
Lymphoid Neoplasm
Interventions
DRUG

Flu-Bu-Mel-E

Fludarabine 150mg/m2, busulfan 6.4mg/kg, melphalan 100mg/m2 and etoposide 600mg/m2

Trial Locations (1)

200025

RECRUITING

Blood & Marrow Transplantation Center, RuiJin Hospital, Shanghai

All Listed Sponsors
lead

Shanghai Jiao Tong University School of Medicine

OTHER